Summary
AbbVie Inc.'s third-quarter 2016 report highlights strong revenue growth, primarily driven by its flagship drug Humira, which saw a 12% increase in global sales. The company also benefited from the recent acquisition of Pharmacyclics and the integration of its product IMBRUVICA, contributing significantly to a 64.5% increase in IMBRUVICA net revenues. Despite these top-line gains, gross margin as a percentage of net revenues declined due to higher intangible asset amortization and acquisition-related costs. Significant strategic moves during the period include the acquisition of Stemcentrx, which expanded AbbVie's oncology pipeline with the addition of rovalpituzumab tesirine (Rova-T), and the acquisition of rights to risankizumab from Boehringer Ingelheim, strengthening its immunology pipeline. AbbVie also continued to return capital to shareholders through dividends and share repurchases, demonstrating a commitment to shareholder value.
Financial Highlights
53 data points| Revenue | $6.43B |
| Cost of Revenue | $1.50B |
| Gross Profit | $4.93B |
| SG&A Expenses | $1.38B |
| Operating Expenses | $4.07B |
| Operating Income | $2.36B |
| Interest Expense | $271.00M |
| Net Income | $1.60B |
| EPS (Basic) | $0.97 |
| EPS (Diluted) | $0.97 |
| Shares Outstanding (Basic) | 1.63B |
| Shares Outstanding (Diluted) | 1.64B |
Key Highlights
- 1Net revenues increased by 8.2% to $6.43 billion for the three months ended September 30, 2016, compared to the prior year period, with a 14.5% increase for the nine months ended September 30, 2016, reaching $18.84 billion.
- 2Humira sales showed robust growth, up 11.3% to $4.06 billion for the quarter and 14.5% to $11.79 billion for the nine months, demonstrating continued market strength.
- 3Imbruvica sales surged by 64.5% to $501 million for the quarter and over 100% to $1.32 billion for the nine months, driven by new indications and market share gains, particularly in first-line CLL treatment.
- 4The acquisition of Stemcentrx in June 2016 significantly expanded AbbVie's oncology pipeline, adding promising assets like Rova-T, with $2.31 billion in goodwill recognized.
- 5Acquisition of rights to risankizumab (BI 655066) from Boehringer Ingelheim in April 2016 bolstered the immunology pipeline, with $3.89 billion in identifiable intangible assets recorded.
- 6Diluted earnings per share (EPS) were $0.97 for the three months ended September 30, 2016, and $2.78 for the nine months ended September 30, 2016.
- 7The company repurchased shares through an accelerated share repurchase (ASR) agreement of $3.8 billion in June 2016 following the Stemcentrx acquisition.